Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.

What the trial testedrandomised · 81,738 people · 2025

Randomised comparison

−5%−9% to −1%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.95, 95% CI 0.91–0.99

the abstract, start to end

… or GLP-1 RAs reduced MACE risk (HR = 0.95, 95% CI 0.91-0.99, P = 0.02).

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.950.91–0.99

MetforminSGLT2 inhibitorsGLP-1 receptor agonistsCardiovascular events

GLP-1 receptor agonists × cardiovascular eventshelps?mixed

unlikelylikely

0.50not counted

Metformin × cardiovascular eventshelps?mixed

unlikelylikely

0.50not counted

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely

0.50not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2025

2026

this paperpooled itcites it